Published online Oct 6, 2021. doi: 10.12998/wjcc.v9.i28.8579
Peer-review started: May 19, 2021
First decision: June 15, 2021
Revised: July 5, 2021
Accepted: July 19, 2021
Article in press: July 19, 2021
Published online: October 6, 2021
Processing time: 131 Days and 15.3 Hours
Infantile hemangiomas (IHs) are the most common childhood benign tumors, showing distinctive progression characteristics and outcomes. Due to the high demand for aesthetics among parents of IH babies, early intervention is critical in some cases. β-Adrenergic blockers and corticosteroids are first-line medications for IHs, while itraconazole, an antifungal medicine, has shown positive results in recent years.
In the present study, itraconazole was applied to treat two IH cases. The therapeutic course lasted 80-90 d, during which the visible lesion faded by more than 90%. Moreover, no obvious side effects were reported, and the compliance of the baby and parents was desirable.
Although these outcomes further support itraconazole as an effective therapeutic choice for IHs, large-scale clinical and basic studies are still warranted to improve further treatment.
Core Tip: Infantile hemangiomas (IHs) stand as the most common vascular tumors in infants, mainly due to the disorder of vascular architecture and aberrant proliferation of endothelial cells. Early intervention is critical for restraining lesion growth, reducing the risk of complications, and mitigating psychosocial stress. In the two IH cases listed in the study, oral administration of itraconazole, which was dissolved in milk for 80-90 d, yielded satisfying outcomes, including fading of lesions by more than 90%, few side effects, and desirable compliance of the baby’s parents. Overall, itraconazole has been demonstrated being an effective therapeutic choice for IHs.